Relationship Between the Expression of PD-1 and CTLA-4 on T Lymphocytes and the Severity and Prognosis of Sepsis

References

• Singer M, Deutschman CS, Seymour CW. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/jama.2016.0287
   PubMed Web of Science ®Google Scholar
• Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211.
   PubMed Web of Science ®Google Scholar
• Mira JC, Gentile LF, Mathias BJ, et al. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome. Crit Care Med. 2017;45(2):253–262.
   PubMed Web of Science ®Google Scholar
• Angus DC, Opal S. Immunosuppression and Secondary Infection in Sepsis: part, Not All, of the Story. JAMA. 2016;315(14):1457–1459.
   PubMed Web of Science ®Google Scholar
• Shankar-Hari M, Harrison DA, Rubenfeld GD, et al. Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database. Br J Anaesth. 2017;119(4):626–636.
   PubMed Web of Science ®Google Scholar
• Patil NK, Bohannon JK, Sherwood ER. Immunotherapy: a promising approach to reverse sepsis-induced immunosuppression. Pharmacol Res. 2016;111:688–702.
   PubMed Web of Science ®Google Scholar
• Shin J, Jin M. Potential Immunotherapeutics for Immunosuppression in Sepsis. Biomol Ther (Seoul). 2017;25(6):569–577.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Wherry EJ. Snap Shot: t Cell Exhaustion. Cell. 2015;163(4):1038.
   PubMed Web of Science ®Google Scholar
• Wakeley ME, Gray CC, Monaghan SF, et al. Check point inhibitors and their role in immunosuppression in sepsis. Crit Care Clin. 2020;36(1):69–88.
   PubMed Web of Science ®Google Scholar
• McBride MA, Patil TK, Bohannon JK, et al. Immune Checkpoints: novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression. Front Immunol. 2021;11:624272.
   PubMed Web of Science ®Google Scholar
• Inoue S, Bo L, Bian J, et al. Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock. 2011;36(1):38–44.
   PubMed Web of Science ®Google Scholar
• Brahmamdam P, Inoue S, Unsinger J, et al. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88(2):233–240.
   PubMed Web of Science ®Google Scholar
• Choi YJ, Kim SB, Kim JH, et al. Impaired polyfunctionality of CD8+ T cells in severe sepsis patients with human cytomegalovirus reactivation. Exp Mol Med. 2017;49(9):e382.
   PubMedGoogle Scholar
• Liu Q, An L, Qi Z, et al. Increased Expression of Programmed Cell Death-1 in Regulatory T Cells of Patients with Severe Sepsis and Septic Shock: an Observational Clinical Study. Scand J Immunol. 2017;86(5):408–417.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Lou J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011;15(1):R70.
   PubMed Web of Science ®Google Scholar
• Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, et al. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care. 2012;16(3):R112.
   PubMed Web of Science ®Google Scholar
• Fallon EA, Biron-Girard BM, Chung CS, et al. A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis. J Leukoc Biol. 2018;1:543.
   Google Scholar
• Rudick CP, Cornell DL, Agrawal DK. Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis. Expert Rev Clin Immunol. 2017;13(9):907–919.
   PubMed Web of Science ®Google Scholar
• Atmatzidis S, Koutelidakis IM, Chatzimavroudis G, et al. Detrimental effect of apoptosis of lymphocytes at an early time point of experimental abdominal sepsis. BMC Infect Dis. 2011;20(11):321.
   Google Scholar
• Karakike E, Kyriazopoulou E, Tsangaris I, et al. The early change of SOFA score as a prognostic marker of 28-day sepsis mortality: analysis through a derivation and a validation cohort. Crit Care. 2019;23(1):387.
   PubMed Web of Science ®Google Scholar
• Green JM. Essentials of sepsis management. Surg Clin North Am. 2015;95(2):355–365.
   PubMed Web of Science ®Google Scholar
• Larsen JB, Laursen MA, Hvas CL, et al. Reduced Mannose-Binding Lectin-Associated Serine Protease (MASP)-1 is Associated with Disturbed Coagulation in Septic Shock. Thromb Haemost. 2019;119(6):952–961.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862–874.
   PubMed Web of Science ®Google Scholar
• Delano MJ, Ward PA. The immune system’s role in sepsis progression, resolution, and long-term outcome. Immunol Rev. 2016;274(1):330–353.
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Coopersmith CM, McDunn JE, et al. The sepsis seesaw: tilting toward immunosuppression. Nat Med. 2009;15(5):496–497.
   PubMed Web of Science ®Google Scholar
• Boomer JS, Green JM, Hotchkiss RS. The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence. 2014;5(1):45–56.
   PubMed Web of Science ®Google Scholar
• Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–2605.
   PubMed Web of Science ®Google Scholar
• Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol. 2007;25:171–192.
   PubMed Web of Science ®Google Scholar
• Gharebaghi N, Valizade Hasanloei MA, Medizadeh Khalifani A, et al. Neutrophil-to-lymphocyte ratio in patients with gram-negative sepsis admitted to intensive care unit. Anaesthesiol Intensive Ther. 2019;51(1):11–16.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Forster R, Prina-Mello A. Intensive care medicine in 2050: nanotechnology. Emerging technologies and approaches and their impact on critical care. Intensive Care Med. 2018;44(8):1299–1301.
   PubMed Web of Science ®Google Scholar
• Ventetuolo CE, Levy MM. Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med. 2008;29(4):591–603, vii.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Beumier M. Diagnostic and prognostic markers in sepsis. Expert Rev Anti Infect Ther. 2013;11(3):265–275.
   PubMed Web of Science ®Google Scholar
• Song J, Park DW, Moon S, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019;19(1):968.
   PubMed Web of Science ®Google Scholar
• Jekarl DW, Lee SY, Lee J, et al. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. Diagn Microbiol Infect Dis. 2013;75(4):342–347.
   PubMed Web of Science ®Google Scholar
• Li Q, Gong X. Clinical significance of the detection of procalcitonin and C-reactive protein in the intensive care unit. Exp Ther Med. 2018;15(5):4265–4270.
   PubMed Web of Science ®Google Scholar
• Candel FJ, Borges M, Belda S, et al. Current aspects in sepsis approach. Turning things around. Rev Esp Quimioter. 2018;31(4):298–315.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Eng J Med. 2015;372(21):2006.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Eng J Med. 2015;372(21):2006–2017.
   PubMed Web of Science ®Google Scholar
• Chang KC, Burnham CA, Compton SM, et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care. 2013;17(3):R85.
   PubMed Web of Science ®Google Scholar
• Danahy DB, Kurup SP, Winborn CS, et al. Sepsis-Induced state of immunoparalysis is defined by diminished cd8 T cell-mediated antitumor immunity. J Immunol. 2019;203(3):725–735.
   PubMed Web of Science ®Google Scholar